<DOC>
	<DOCNO>NCT00003703</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness chemotherapy use sarCNU patient advance solid tumor .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose SarCNU patient advance solid malignancy . II . Determine toxic effect SarCNU patient . III . Characterize pharmacokinetic profile regimen patient . IV . Determine evidence antineoplastic activity regimen patient . OUTLINE : This dose-escalation study . Patients receive oral SarCNU day 1 , 5 , 9 . Treatment continue every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SarCNU maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat MTD . PROJECTED ACCRUAL : Approximately 12-36 patient accrue study .</detailed_description>
	<mesh_term>2- ( ( ( ( 2-chloroethyl ) nitrosoamino ) carbonyl ) amino ) propanamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid malignancy curative lifeextending therapy exist No prior concurrent CNS metastases Primary CNS tumor allow stable dose steroid least 2 week study entry No myelodysplastic syndrome PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 120,000/mm3 Hemoglobin great 8 g/dL Hepatic : Bilirubin normal AST ALT less 2.5 time upper limit normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No uncontrolled cardiac disease No uncontrolled hypertension Pulmonary : DLCO vital capacity great 80 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative Oral intake least 1,200 calorie per day No recent weight loss 10 % actual body weight No serious concurrent illness No uncontrolled infection PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy No concurrent immunotherapy No concurrent immunomodulating agent Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent cytostatic cytotoxic chemotherapy Endocrine therapy : See Disease Characteristics No concurrent hormonal therapy No concurrent dexamethasone Radiotherapy : At least 3 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery : At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>